April 4, 2019

A joint HMA and EMA taskforce analyzes the use of big data for the evaluation and monitoring of medicines

The Joint Big Data taskforce (“Taskforce”) between the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) was formed to describe the big data landscape from a regulatory perspective in order to ensure that the EU regulatory system has the capability and capacity to guide, analyze and interpret this data. Its work aims to facilitate the use of such data for the process of evaluation and monitoring of medicines by the regulatory authorities, analyzing the risk-benefit of medicinal products during their lifetime.

On February 15, 2019, the Taskforce issued a report with a number of recommendations and associated actions that set out needs to be addressed, although the mechanisms by which these may be achieved require further focused work over the coming year. Since the term “big data” is widely used but lacks a commonly accepted definition, this Report provides a definition of big data as «extremely large datasets which may be complex, multi-dimensional, unstructured and heterogeneous, which are accumulating rapidly and which may be analyzed computationally to reveal patterns, trends, and associations».

In particular, the Taskforce takes into account the considerable amount of data deriving from wearable devices, electronic health records, social media and clinical trials and assesses how to utilize it for regulatory purposes. The description carried out by the Taskforce focused on six data subgroups: genomics, bioanalytical ‘omics, clinical trials, observational data, data on spontaneous adverse drug reactions and social media and m-health data.

For instance, with regard to data standardization, the Taskforce suggests promoting the use of global, harmonized and comprehensive standards to facilitate interoperability of data. Secondly, with respect to data quality, the Taskforce specifies that characterization of data quality across multiple data sources is essential in order to fully understand the reliability of the evidence. Additionally, it recommends the development of timely, efficient and sustainable frameworks for data sharing and access, as well as to further support mechanisms to promote a culture of data sharing.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

March 20, 2023
Today, Regulation (EU) 2023/607 extending the transitional provisions for the placing on the market and putting into service of certain medical devices and in vitro diagnostic medical device...
January 31, 2023
Clinical trials: Ministry of Health signed off on decrees that (i) reorganize ethics committees and coordinate their activities, (ii) determine the single tariff for the authorization proced...
December 19, 2022
On 13 December 2022, EMA, European Commission and HMA jointly adopted a recommendation paper on the introduction of decentralised elements in the conduct of Clinical Trials in the EU/EEA
September 21, 2022
Payback for medical devices: Decree quantifying the exceeding of the expenditure ceiling for medical devices at national and regional level for the years 2015, 2016, 2017 and 2018 published ...
September 1, 2022
The 2021 annual law for market and competition addressing, as to the healthcare sector, reimbursement of drugs, intermediate distribution, patent linkage and institutional accreditation of p...
Search by...
Follow us on
Follow us on